Tag: HRS 2026
Data shared at HRS 2026 highlight pitfalls of short-term Holter monitoring...
iRhythm Holdings has announced results from two real-world retrospective analyses in post-ablation and pregnancy patient populations presented at the 2026 Heart Rhythm Society (HRS)...
AI-driven analysis finds no link between AF burden and stroke risk...
A new analysis from the NOAH-AFNET 6 trial has shown that artificial intelligence (AI) can help unlock data from pacemakers to better understand stroke...
Ultra-low-temperature ablation is highly effective for ventricular tachycardia, study finds
New results from a pivotal multicentre trial—FULCRUM-VT—show that ultra-low-temperature ablation (ULTA) may offer a promising new treatment option for patients with ventricular tachycardia (VT)...
Smartwatch captures more paediatric arrhythmia events than traditional patch monitors
A new study examining the accuracy of wearable technologies for capturing irregular heartbeats in children has found that the Apple Watch (Apple) can potentially...
Catheter ablation reduces ventricular tachycardia events in study including underrepresented patient...
New results from the multicentre CAAD-VT trial show that catheter ablation may reduce ventricular tachycardia (VT) events in patients with ischaemic and non-ischaemic cardiomyopathy....
Structured care pathways help hospitals increase usage of early rhythm control...
The Heart Rhythm Society (HRS) has announced the first analysis of its COMPASS initiative, which is evaluating the impact of structured care pathways for...
Large-scale study links GLP-1 receptor agonists to reduced AF risk—independent of...
A new study analysing data from more than 13,000 patients has found that people using the increasingly popular weight-loss drugs known as glucagon-like peptide-1...
Abbott announces positive data on multiple pulsed field ablation and conduction...
Abbott has announced late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP)...
J&J launches “landmark” head-to-head pulsed field ablation trial in persistent AF
Johnson & Johnson (J&J) has announced the initiation of the PERSIGMA randomised controlled trial (RCT)—one of the first randomised studies evaluating competitive pulsed field...
Boston shares plethora of new findings on Farapulse PFA and Watchman...
Boston Scientific Corporation has announced data supporting the use of the company's Farapulse pulsed field ablation (PFA) platform and Watchman left atrial appendage closure...
Medtronic announces new clinical data on Affera ablation technologies
Medtronic has announced continued momentum regarding its Affera family of technologies for cardiac arrhythmia treatment, including promising data presented at the Heart Rhythm Society...